NeuroPace, Inc.
NPCEHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeNeuroPace, Inc. operates as a medical device company in the United States. The company carries a $443.1M market cap, placing it firmly in the small-cap category. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Market Cap
$443.1M
Beta
1.87
P/E (TTM)
—
P/E (Fwd)
-59.36
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.22
ROE
-103.3%
ROA
-7.5%
Cash
$51.7M
Total Debt
$69.9M
Free CF
-$2.6M
52W Change
21.8%
Annual Financials
Cash vs Debt
Where NPCE stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, NPCE finished 16.20% below its 150-day moving average ($15.12) and 16.81% below its 200-day moving average ($15.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NPCE overbought or oversold?
At the October 12, 2026 close, NPCE's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NeuroPace, Inc. carries $69.9M in total debt against $51.7M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$2.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -103.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $45.5M (2022) to $100.0M (2025), reflecting a 120% increase over the period.
A beta of 1.87 means NPCE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NPCE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.